Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Amneal Pharmaceuticals, Inc.
Report date May 04, 2020 · Filed May 05, 2020
Section 16 reporting ended · disclosed 2020-05-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 82,758 |
Reported balance
After 2020-05-04 transaction · row 1
1 source rowRow 1 · 2020-05-04 · Exercise / conversion · Acquired 6,459 · Balance 82,758 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-04 · Exercise / conversion · Disposed 6,459 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2: On May 6, 2019, the reporting person was granted 6,459 restricted stock units. Because the reporting person did not stand for election at the annual meeting on May 5, 2020, the restricted stock units vested on May 4, 2020 (the day prior to the first annual meeting of stockholders following the date of grant). |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F2: On May 6, 2019, the reporting person was granted 6,459 restricted stock units. Because the reporting person did not stand for election at the annual meeting on May 5, 2020, the restricted stock units vested on May 4, 2020 (the day prior to the first annual meeting of stockholders following the date of grant).
Impax Laboratories, LLC
Report date May 04, 2018 · Filed May 08, 2018
Section 16 reporting ended · disclosed 2018-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 1
1 source rowRow 1 · 2018-05-04 · Disposition to issuer · Disposed 43,129 · Balance 0 F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). |
| Restricted Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 2
1 source rowRow 2 · 2018-05-04 · Disposition to issuer · Disposed 5,408 · Balance 0 F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40 · Expires 2027-05-16 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-05-04 · Disposition to issuer · Disposed 10,575 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.33 · Expires 2026-05-17 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-05-04 · Disposition to issuer · Disposed 10,575 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.85 · Expires 2025-05-12 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-05-04 · Disposition to issuer · Disposed 7,300 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.24 · Expires 2024-05-14 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-05-04 · Disposition to issuer · Disposed 11,500 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.99 · Expires 2023-05-15 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-05-04 · Disposition to issuer · Disposed 12,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.90 · Expires 2022-05-23 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-05-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.97 · Expires 2021-05-11 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-05-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.30 · Expires 2020-05-26 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-05-04 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.55 · Expires 2019-05-20 | Direct | 0 |
Reported balance
After 2018-05-04 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-05-04 · Disposition to issuer · Disposed 45,000 · Balance 0 F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. |
Filing footnotes · ownership attribution and instrument terms
F1: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock").
F2: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock.
F3: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2020 Filed May 5, 2020 20:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012068 · doc4.xml · derivative · entry 2 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 6, 2019, the reporting person was granted 6,459 restricted stock units. Because the reporting person did not stand for election at the annual meeting on May 5, 2020, the restricted stock units vested on May 4, 2020 (the day prior to the first annual meeting of stockholders following the date of grant). F2 · derivative.expiration_date: On May 6, 2019, the reporting person was granted 6,459 restricted stock units. Because the reporting person did not stand for election at the annual meeting on May 5, 2020, the restricted stock units vested on May 4, 2020 (the day prior to the first annual meeting of stockholders following the date of grant). Read SEC document |
| May 04, 2020 Filed May 5, 2020 20:23 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 6,459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012068 · doc4.xml · nonDerivative · entry 1 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000067 · wf-form4_155735197842483.xml · derivative · entry 4 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 6,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001723128-19-000067 · wf-form4_155735197842483.xml · nonDerivative · entry 1 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000067 · wf-form4_155735197842483.xml · derivative · entry 3 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 Underlying: Class A Common Stock · 6,459 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 28,044 | $0.00 Strike: $14.05 | $0.00 |
DisclosureSEC source: 0001723128-19-000067 · wf-form4_155735197842483.xml · derivative · entry 2 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,044 Underlying: Class A Common Stock · 28,044 shares Expires 2029-05-06 F2 · derivative.exercise_date: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| March 06, 2019 Filed Mar 7, 2019 22:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionStock Option · Derivative | 45,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001723128-19-000038 · wf-form4_155199847854964.xml · derivative · entry 3 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 45,000 shares Expires 2019-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| March 06, 2019 Filed Mar 7, 2019 22:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 45,000 | $6.55 | $294,750.00 |
DisclosureSEC source: 0001723128-19-000038 · wf-form4_155199847854964.xml · nonDerivative · entry 2 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,192 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2019 Filed Mar 7, 2019 22:41 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | SaleClass A Common Stock | 23,345 | $12.39 | $289,244.55 |
DisclosureSEC source: 0001723128-19-000038 · wf-form4_155199847854964.xml · nonDerivative · entry 1 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,192 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.39 per share to $12.38 per share. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc., any security holder of Amneal Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 07, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · derivative · entry 12 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. Read SEC document |
| May 07, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 24,977 | $0.00 Strike: $15.01 | $0.00 |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · derivative · entry 11 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,977 Underlying: Class A Common Stock · 24,977 shares Expires 2028-05-07 F4 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:27 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 45,000 | Not disclosed Strike: $6.55 | Not disclosed |
DisclosureSEC source: 0001003642-18-000088 · wf-form4_152581125121121.xml · derivative · entry 11 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2019-05-20 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:27 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $20.30 | Not disclosed |
DisclosureSEC source: 0001003642-18-000088 · wf-form4_152581125121121.xml · derivative · entry 10 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2020-05-26 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:27 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $27.97 | Not disclosed |
DisclosureSEC source: 0001003642-18-000088 · wf-form4_152581125121121.xml · derivative · entry 9 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2021-05-11 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:27 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $20.90 | Not disclosed |
DisclosureSEC source: 0001003642-18-000088 · wf-form4_152581125121121.xml · derivative · entry 8 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2022-05-23 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:27 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $17.99 | Not disclosed |
DisclosureSEC source: 0001003642-18-000088 · wf-form4_152581125121121.xml · derivative · entry 7 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2023-05-15 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:27 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 11,500 | Not disclosed Strike: $25.24 | Not disclosed |
DisclosureSEC source: 0001003642-18-000088 · wf-form4_152581125121121.xml · derivative · entry 6 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,500 shares Expires 2024-05-14 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:27 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,300 | Not disclosed Strike: $44.85 | Not disclosed |
DisclosureSEC source: 0001003642-18-000088 · wf-form4_152581125121121.xml · derivative · entry 5 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,300 shares Expires 2025-05-12 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:27 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,575 | Not disclosed Strike: $30.33 | Not disclosed |
DisclosureSEC source: 0001003642-18-000088 · wf-form4_152581125121121.xml · derivative · entry 4 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,575 shares Expires 2026-05-17 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:27 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,575 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0001003642-18-000088 · wf-form4_152581125121121.xml · derivative · entry 3 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,575 shares Expires 2027-05-16 F3 · shares: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · price: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. F3 · derivative.exercise_date: Options disposed of pursuant to the terms of the BCA, according to which each Option held by the reporting person fully vested and was exchanged for an option to acquire a number of shares of Class A Common Stock equal to the number of shares of Common Stock subject to such Option in connection with the closing of the transactions contemplated by the BCA, at a per-share exercise price equal to the per-share exercise price of such Option. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:27 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerRestricted Common Stock | 5,408 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000088 · wf-form4_152581125121121.xml · nonDerivative · entry 2 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · shares: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. F2 · price: Shares of restricted common stock disposed of pursuant to the terms of the BCA, according to which each share of restricted stock held by the reporting person fully vested and was exchanged for one share of Class A Common Stock. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:27 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | Disposition to issuerCommon Stock | 43,129 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001003642-18-000088 · wf-form4_152581125121121.xml · nonDerivative · entry 1 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). F1 · price: Common Stock disposed of pursuant to the terms of the Business Combination Agreement, dated as of October 17, 2017 (the "BCA"), by and among Impax Laboratories, Inc., Atlas Holdings, Inc. ("Holdco"), K2 Merger Sub Corporation and Amneal Pharmaceuticals LLC, as amended by Amendment No. 1, dated as of November 21, 2017, and Amendment No. 2, dated as of December 16, 2017, according to which each share of Common Stock held by the reporting person was converted into the right to receive one share of Class A common stock of Holdco ("Class A Common Stock"). Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 45,000 | Not disclosed Strike: $6.55 | Not disclosed |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · derivative · entry 10 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Class A Common Stock · 45,000 shares Expires 2019-05-20 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,000 | Not disclosed Strike: $20.30 | Not disclosed |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · derivative · entry 9 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 10,000 shares Expires 2020-05-26 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,000 | Not disclosed Strike: $27.97 | Not disclosed |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · derivative · entry 8 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 10,000 shares Expires 2021-05-11 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,000 | Not disclosed Strike: $20.90 | Not disclosed |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · derivative · entry 7 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 10,000 shares Expires 2022-05-23 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 12,000 | Not disclosed Strike: $17.99 | Not disclosed |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · derivative · entry 6 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Class A Common Stock · 12,000 shares Expires 2023-05-15 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 11,500 | Not disclosed Strike: $25.24 | Not disclosed |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · derivative · entry 5 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Class A Common Stock · 11,500 shares Expires 2024-05-14 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 7,300 | Not disclosed Strike: $44.85 | Not disclosed |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · derivative · entry 4 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,300 Underlying: Class A Common Stock · 7,300 shares Expires 2025-05-12 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,575 | Not disclosed Strike: $30.33 | Not disclosed |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · derivative · entry 3 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575 Underlying: Class A Common Stock · 10,575 shares Expires 2026-05-17 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 10,575 | Not disclosed Strike: $16.40 | Not disclosed |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · derivative · entry 2 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575 Underlying: Class A Common Stock · 10,575 shares Expires 2027-05-16 F3 · price: Received pursuant to the BCA in exchange for an option to purchase an equal number of shares of Impax common stock. F2 · derivative.exercise_date: The option is vested and currently exercisable. Read SEC document |
| May 04, 2018 Filed May 8, 2018 23:25 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantClass A Common Stock | 48,537 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-011946 · doc4.xml · nonDerivative · entry 1 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,537 F1 · price: Received in exchange for 48,537 shares of Impax Laboratories, Inc. ("Impax") common stock pursuant to the Business Combination Agreement, dated as of October 17, 2017, among Impax, Amneal Pharmaceuticals LLC, Atlas Holdings, Inc. and K2 Merger Sub Corporation (as amended, the "BCA"). Read SEC document |
| May 16, 2017 Filed May 17, 2017 15:51 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantStock Option (Right-to-Buy) · Derivative | 10,575 | $0.00 Strike: $16.40 | $0.00 |
DisclosureSEC source: 0001003642-17-000056 · wf-form4_149505067519184.xml · derivative · entry 2 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,575 Underlying: Common Stock · 10,575 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option fully vests on the earlier of (i) May 16, 2018 which is the first anniversary of the date of grant and (ii) one day before the date of the Company's next annual meeting of stockholders. Read SEC document |
| May 16, 2017 Filed May 17, 2017 15:51 UTC | Impax Laboratories, LLC IPXL · Entity 14052 | GrantCommon Stock | 4,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001003642-17-000056 · wf-form4_149505067519184.xml · nonDerivative · entry 1 TERRERI PETER R · CIK 0001238456 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,537 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.